Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
269
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility

Daniel M. GuidotWinship Cancer Institute, Emory University, Atlanta, GA, USA; ORCID Iconhttp://orcid.org/0000-0002-3165-2496View further author information
ORCID Icon,
Jeffrey M. SwitchenkoDepartment of Biostatistics, Emory University, Atlanta, GA, USA; View further author information
,
Loretta J. NastoupilMD Anderson Cancer Center, University of Texas, Houston, TX, USA; View further author information
,
Jean L. KoffWinship Cancer Institute, Emory University, Atlanta, GA, USA; ORCID Iconhttp://orcid.org/0000-0003-4414-0489View further author information
ORCID Icon,
Kristie A. BlumJames Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USAView further author information
,
Joseph MalyJames Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USAView further author information
,
Christopher R. FlowersWinship Cancer Institute, Emory University, Atlanta, GA, USA; View further author information
&
Jonathon B. CohenWinship Cancer Institute, Emory University, Atlanta, GA, USA; Correspondence[email protected]
View further author information
 show all
Pages 888-895 | Received 03 Jul 2017, Accepted 23 Jul 2017, Published online: 10 Aug 2017

References

  • Nastoupil LJ, Shenoy PJ, Ambinder A, et al. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma. 2015;56:383–389.
  • Eskelund CW, Kolstad A, Jerkeman M, et al. 15-Year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410–418.
  • Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013;121:48–53.
  • Cohen JB, Ruppert AS, Heerema NA, et al. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. Clin Lymph Myeloma Leuk. 2015;15:278–285.
  • Cheah C, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–1269.
  • Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol. 2011;86:841–845.
  • Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma. 2008;49:1693–1701.
  • Gill S, Wolf M, Prince HM, et al. [18F]fluorodeoxyglu-cose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymph Myeloma. 2008;8:159–165.
  • Cheung MC, Mittmann N, Earle C, et al. Are we choosing wisely in lymphoma? Excessive use of surveillance CT imaging in patients with diffuse large b-cell lymphoma (DLBCL) in long-term remission. Blood. 2016;128:692.
  • Thompson CA, Ghesguieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. JCO. 2014;32:3506–3512.
  • Cohen JB, Behera M, Thompson CA, et al. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood. 2017;129(5):561–564.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification. JCO. 2014;32:3048–3058.
  • Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin’s lymphomas, version 4. J Natl Comprehens Cancer Netw. 2014;12:1282–1303.
  • Kolstad A, Pedersen LB, Eskulund CW, et al. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Bone Marrow Transplant. 2017;23:428–435.
  • Holster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematology Am Soc Hematol Educ Prog. 2016;2016(1):437–445.
  • Cowan AJ, Stevenson PA, Cassaday RD, et al. Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission. Biol Blood Bone Marrow Transplant. 2016;22:380–385.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.